Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients

摘要

The present invention relates to methods for prognosis and/or predicted outcome of treatment with estrogen treatment of breast cell proliferative disorder patients, in particular breast carcinoma. This is achieved by determining the expression level of PITX2 or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.